
BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
pharmafile | September 5, 2019 | News story | Research and Development | BMS, glioblastoma multiforme, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the treatment of newly diagnosed glioblastoma multiforme (GBM) when combined with the current standard of care, temozolomide and radiation therapy).
The manufacturer revealed that its combo failed to show adequate benefit in progression-free survival (PFS) in patients with GBM that is O6-methylguanine-DNA methyltransferase (MGMT)-methylated, compared to standard of care alone.
Despite the failure, BMS confirmed that the trial would continue under recommendation from the data monitoring committee in order to allow data to mature and meet its other primary endpoint of overall survival.
“Though CheckMate -548 did not show statistically significant improvement in progression-free survival, we are continuing to evaluate the benefit the addition of Opdivo to the standard of care treatment regimen may bring to patients suffering from GBM, an extremely aggressive and difficult disease to treat. We look forward to seeing the overall survival data when they are available,” commented Dr Fouad Namouni, Head of Oncology Development at Bristol-Myers Squibb. “We are grateful to the patients, caregivers and investigators participating in this trial who make this research possible.”
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …






